Cantor Fitzgerald Reiterates Overweight on Abeona Therapeutics, Maintains $38 Price Target
Portfolio Pulse from richadhand@benzinga.com
Cantor Fitzgerald analyst Kristen Kluska has reiterated an Overweight rating on Abeona Therapeutics (NASDAQ:ABEO) and maintained a $38 price target.
July 13, 2023 | 12:56 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Cantor Fitzgerald has reiterated an Overweight rating on Abeona Therapeutics and maintained a $38 price target.
The reiteration of an Overweight rating by Cantor Fitzgerald indicates a positive outlook for Abeona Therapeutics. The maintained price target of $38 suggests that the analyst believes the stock has potential for growth. This could lead to increased investor confidence and potentially a rise in the stock's price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100